These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 30277128)

  • 1. Mesenchymal stem cells in myeloproliferative disorders - focus on primary myelofibrosis.
    Selicean SE; Tomuleasa C; Grewal R; Almeida-Porada G; Berindan-Neagoe I
    Leuk Lymphoma; 2019 Apr; 60(4):876-885. PubMed ID: 30277128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.
    Rambaldi B; Diral E; Donsante S; Di Marzo N; Mottadelli F; Cardinale L; Dander E; Isimbaldi G; Pioltelli P; Biondi A; Riminucci M; D'Amico G; Elli EM; Pievani A; Serafini M
    Ann Hematol; 2021 Jan; 100(1):105-116. PubMed ID: 33089365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.
    Fisher DAC; Fowles JS; Zhou A; Oh ST
    Front Immunol; 2021; 12():683401. PubMed ID: 34140953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of hematopoietic stem cell transplant on splenic extramedullary hematopoiesis in patients with myeloproliferative neoplasm-associated myelofibrosis.
    Pizzi M; Gergis U; Chaviano F; Orazi A
    Hematol Oncol Stem Cell Ther; 2016 Sep; 9(3):96-104. PubMed ID: 27521149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Myeloproliferative disorders].
    Binder D; Fehr J
    Ther Umsch; 2004 Feb; 61(2):131-42. PubMed ID: 15018396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canonical Wnt/β-Catenin Signaling Pathway Is Dysregulated in Patients With Primary and Secondary Myelofibrosis.
    Lucijanic M; Livun A; Tomasovic-Loncaric C; Stoos-Veic T; Pejsa V; Jaksic O; Prka Z; Kusec R
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):523-526. PubMed ID: 27381374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis.
    Desterke C; Martinaud C; Ruzehaji N; Le Bousse-Kerdilès MC
    Mediators Inflamm; 2015; 2015():415024. PubMed ID: 26640324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies.
    Zahr AA; Salama ME; Carreau N; Tremblay D; Verstovsek S; Mesa R; Hoffman R; Mascarenhas J
    Haematologica; 2016 Jun; 101(6):660-71. PubMed ID: 27252511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TGF-β signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche.
    Yao JC; Oetjen KA; Wang T; Xu H; Abou-Ezzi G; Krambs JR; Uttarwar S; Duncavage EJ; Link DC
    J Clin Invest; 2022 Jun; 132(11):. PubMed ID: 35439167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The identification of fibrosis-driving myofibroblast precursors reveals new therapeutic avenues in myelofibrosis.
    Kramann R; Schneider RK
    Blood; 2018 May; 131(19):2111-2119. PubMed ID: 29572380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
    Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
    Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCN2/CTGF expression does not correlate with fibrosis in myeloproliferative neoplasms, consistent with noncanonical TGF-β signaling driving myelofibrosis.
    Leguit RJ; Broekhuizen R; de Witte M; Raymakers RAP; Goldschmeding R
    Virchows Arch; 2024 May; 484(5):837-845. PubMed ID: 38602559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.
    Yan D; Pomicter AD; Tantravahi S; Mason CC; Senina AV; Ahmann JM; Wang Q; Than H; Patel AB; Heaton WL; Eiring AM; Clair PM; Gantz KC; Redwine HM; Swierczek SI; Halverson BJ; Baloglu E; Shacham S; Khorashad JS; Kelley TW; Salama ME; Miles RR; Boucher KM; Prchal JT; O'Hare T; Deininger MW
    Clin Cancer Res; 2019 Apr; 25(7):2323-2335. PubMed ID: 30563936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Still a burning question: the interplay between inflammation and fibrosis in myeloproliferative neoplasms.
    Gleitz HFE; Benabid A; Schneider RK
    Curr Opin Hematol; 2021 Sep; 28(5):364-371. PubMed ID: 34232140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inability of immunomorphometric assessment of angiogenesis to distinguish primary versus secondary myelofibrosis.
    Sharma P; Pati HP; Mishra PC; Dinda AK; Gupta R; Sharma A; Jacob TG
    Anal Quant Cytol Histol; 2011 Aug; 33(4):236-44. PubMed ID: 21980629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology.
    Eran Z; Zingariello M; Bochicchio MT; Bardelli C; Migliaccio AR
    F1000Res; 2019; 8():. PubMed ID: 31583083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelofibrosis revisited: characterization and classification of myelofibrosis in the setting of myeloproliferative disease.
    Gilbert HS
    Prog Clin Biol Res; 1984; 154():3-17. PubMed ID: 6382299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis.
    Martinaud C; Desterke C; Konopacki J; Vannucchi AM; Pieri L; Guglielmelli P; Dupriez B; Ianotto JC; Boutin L; Lataillade JJ; Le Bousse-Kerdilès MC
    Genom Data; 2015 Sep; 5():1-2. PubMed ID: 26484208
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Xiao P; Dolinska M; Sandhow L; Kondo M; Johansson AS; Bouderlique T; Zhao Y; Li X; Dimitriou M; Rassidakis GZ; Hellström-Lindberg E; Minato N; Walfridsson J; Scadden DT; Sigvardsson M; Qian H
    Blood Adv; 2018 Mar; 2(5):534-548. PubMed ID: 29514790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline mutations in the bone marrow microenvironment and dysregulated hematopoiesis.
    Miller LH; Qu CK; Pauly M
    Exp Hematol; 2018 Oct; 66():17-26. PubMed ID: 30076950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.